APCCC 2024 | Skipping extended pelvic lymph node dissection with negative PSMA PET in prostate cancer

Declan Murphy • 30 Apr 2024

APCCC 2024

Declan Murphy, FRACS, FRCS, Peter MacCallum Cancer Centre, Melbourne, Australia, explains the rationale for skipping extended pelvic lymph node dissection in high-risk patients with prostate cancer with negative prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scans. Pelvic lymph node dissection does not improve survival and increases complications. The 2024 European Association of Urology guidelines now reduce recommendations for lymph node dissection, particularly in intermediate-risk cases. PSMA PET/CT is advocated to guide decisions and avoid unnecessary procedures. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.